NYSE:CRL - Charles River Laboratories Intl. Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$116.93 +0.96 (+0.83 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$115.97
Today's Range$115.85 - $117.26
52-Week Range$94.15 - $119.05
Volume260,375 shs
Average Volume375,800 shs
Market Capitalization$5.58 billion
P/E Ratio22.11
Dividend YieldN/A
Beta0.7
Charles River Laboratories Intl. logoCharles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000

Debt

Debt-to-Equity Ratio0.99
Current Ratio2.07
Quick Ratio1.78

Price-To-Earnings

Trailing P/E Ratio22.11
Forward P/E Ratio20.09
P/E Growth1.48

Sales & Book Value

Annual Sales$1.86 billion
Price / Sales3.02
Cash Flow$8.1999 per share
Price / Cash14.26
Book Value$22.11 per share
Price / Book5.29

Profitability

EPS (Most Recent Fiscal Year)$5.27
Net Income$123.35 million
Net Margins6.78%
Return on Equity24.96%
Return on Assets9.02%

Miscellaneous

Employees11,800
Outstanding Shares47,910,000

Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories Intl.'s stock buyback program work?

Charles River Laboratories Intl. declared that its board has authorized a stock repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) released its quarterly earnings data on Thursday, May, 10th. The medical research company reported $1.38 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.26 by $0.12. The medical research company had revenue of $493.97 million for the quarter, compared to analyst estimates of $480.03 million. Charles River Laboratories Intl. had a net margin of 6.78% and a return on equity of 24.96%. Charles River Laboratories Intl.'s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.29 EPS. View Charles River Laboratories Intl.'s Earnings History.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Charles River Laboratories Intl..

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. issued an update on its FY18 earnings guidance on Thursday, May, 10th. The company provided earnings per share guidance of $5.77-5.92 for the period, compared to the Thomson Reuters consensus estimate of $5.71. The company issued revenue guidance of $2.19-2.23 billion (+18-20%), compared to the consensus revenue estimate of $2.15 billion.

What price target have analysts set for CRL?

14 Wall Street analysts have issued 12 month target prices for Charles River Laboratories Intl.'s stock. Their forecasts range from $102.00 to $130.00. On average, they anticipate Charles River Laboratories Intl.'s stock price to reach $116.7857 in the next year. View Analyst Ratings for Charles River Laboratories Intl..

Who are some of Charles River Laboratories Intl.'s key competitors?

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:
  • Mr. James C. Foster, Chairman & CEO (Age 67)
  • Dr. Davide A. Molho, Pres & COO (Age 48)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 52)
  • Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 57)

Has Charles River Laboratories Intl. been receiving favorable news coverage?

News coverage about CRL stock has been trending positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Charles River Laboratories Intl. earned a daily sentiment score of 0.44 on Accern's scale. They also gave news stories about the medical research company an impact score of 47.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.76%), Wells Fargo & Company MN (2.63%), Neuberger Berman Group LLC (1.44%), Van Berkom & Associates Inc. (1.29%), Dimensional Fund Advisors LP (1.11%) and Lord Abbett & CO. LLC (0.99%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Which institutional investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prudential Financial Inc., FIL Ltd, JPMorgan Chase & Co., Fisher Asset Management LLC, Hood River Capital Management LLC, Neuberger Berman Group LLC and Victory Capital Management Inc.. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Which institutional investors are buying Charles River Laboratories Intl. stock?

CRL stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, DekaBank Deutsche Girozentrale, Massachusetts Financial Services Co. MA, BlackRock Inc., Great Lakes Advisors LLC, Russell Investments Group Ltd., Barclays PLC and Allianz Asset Management GmbH. Company insiders that have bought Charles River Laboratories Intl. stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $116.93.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $5.58 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories Intl. employs 11,800 workers across the globe.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.